Business Wire

Travelopia Takes Next Steps On Customer Experience Journey With Talkdesk

Share

Talkdesk®, Inc., the global customer experience leader for customer-obsessed companies, has been chosen by Travelopia, the world’s largest collection of specialist travel brands, as its contact centre solution provider. Talkdesk provided a flexible, scalable solution as this pioneer in specialty travel charted a new course to remote call center technology for its portfolio of independent brands operating across the globe.

Travelopia - the only travel brand of its kind in the world - is at the forefront of global travel for those wanting a distinctive experience. With primary headquarters in Crawley, England, the company supports a global network of hospitality professionals representing 23 independent travel brands offering more than 70 destinations, spanning 10 countries across all seven continents. The Travelopia portfolio is exclusively focused on specialist travel, and the company strives to deliver unique experiences - from exploring Canada’s Rideau Canal by boat to joining the ranks of those rare travellers who cross the Antarctic Circle to see the South Pole. Whether travelling around the world by private jet or exploring closer to home on bicycle, Travelopia helps cultivate the passions and interests of its more than 750,000 guests each year.

Talkdesk CX Cloud™, an end-to-end customer experience solution, made the transition from on premises to remote contact centre operations much easier for the geographically diverse Travelopia network of sales agents responsible for helping guests with highly customised travel itineraries and complex customer support enquiries. Agents across multiple geographies could better manage their time, which reduced the number of missed guest calls. The Talkdesk solution offered robust analytics, and those deeper insights into customer data enabled agents to proactively suggest new, customised travel experiences for returning guests. The flexibility and scalability of remote contact centre operations allowed Travelopia to efficiently adapt to the rapidly changing travel market conditions over the last year, as well as lowered operating costs during a volatile time for the travel industry as a whole.

“One of the core values driving Travelopia forward is our constant pursuit of the ultimate customer experience for our guests to enrich their lives through travel. As part of that pursuit, we’re committed to reflect on and evolve our operational approach,” said Mark Beauchamp, technology director, Travelopia. “For our move to remote contact centre operations, we wanted an innovative, flexible solution with the best tools to delight our customers. The Talkdesk solution provides our global network of agents across the portfolio of Travelopia brands with the resources they need to provide a seamless customer journey for guests - from first contact with our sales team through to the conclusion of that world beating travel experience.”

“Customer experience has never been more important to the success of travel and hospitality brands as it is now. Travellers worldwide are making up for lost time and missed opportunities, and they will choose to partner with those companies that can deliver not only that once-in-a-lifetime adventure, but also an unforgettable customer service experience before, during, and after,” said Kieran King, chief customer officer, Talkdesk. “With the Talkdesk solution, Travelopia agents can provide customer experience as unique and meaningful as the extraordinary travel experiences they create. We’re proud to partner with Travelopia in achieving their customer experience goals.”

Additional Resources

Social Networks

About Talkdesk

Talkdesk® is a global cloud contact center leader for customer-obsessed companies. We believe that better customer experiences start with AI. Our automation-first customer experience solutions optimize our customers’ most critical customer service processes. Our speed of innovation, deep vertical expertise, and global footprint reflect our commitment to ensuring that businesses everywhere can deliver better customer experiences across any industry and through any channel, resulting in higher customer satisfaction and accelerated business outcomes. Over 1,800 innovative companies around the world, including Acxiom, Fujitsu, Hunter Douglas, IBM, Trivago, Tuft & Needle, YMCA, and 2U partner with Talkdesk to deliver a better way to great customer experience. Learn more and request a demo at www.talkdesk.com.

Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered ® trademarks of their respective holders. Use of them does not imply any affiliation or endorsement by them.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

EMEA
Samantha Cupples
samantha.cupples@talkdesk.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye